TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34782430
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccine targeting tumor blood vessel antigens with delayed dasatinib (Arm A)
Study: 35347874
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for MDD
Study: 32179446
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) with 4x TC, interval debulking surgery (IDS), 4x TC
Study: 32378422
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral melatonin supplementation
Study: 33864989
Drug: MISSION‐CJ (wraparound
Approvals — FDA: no, EMA: no, PMDA: no
Description: MISSION‐CJ (wraparound treatment)
Study: 32981534
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation and LAI antipsychotic medication
Study: 34284802
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus behaviour change therapy
Study: 35585981
Drug: Normothermic machine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normothermic machine perfusion (NMP) with oxygenated banked red blood cell (RBC) based solution for 1h at 36°C
Study: 35230884
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (40 mg/m2)
Study: 35230884
Drug: 3-weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly cisplatin (100 mg/m2)
Study: 39141622
Drug: Sleep Restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep Restriction Therapy (SRT)
Study: 33110130
Drug: Atropine treatment
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine treatment after 3 and 6 months
Study: 34506986
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (15 mg every 6 hours)
Study: 33792832
Drug: Placebo, orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally three times daily
Study: 35411402
Drug: Remote antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote antibiotic stewardship program (ASP)
Study: 33989812
Drug: Nebulized low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized low molecular weight heparin (1 mg/kg) with albuterol (2.5 mg) every 20 min for 10 min
Study: 32183861
Drug: Various intravenous
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various intravenous iron preparations
Study: 37078188
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTI)
Study: 33784989
Drug: Dienogest 2
Normalized name: dienogest 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest 2 mg/d for 3 months
Study: 32000598
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 10mg/ml triamcinolone acetate (CS)
Study: 35122992
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg wheat flour for 4 weeks)
Study: 34642366
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intermittent radiation treatment (iRT, [Formula: see text] Gy [Formula: see text] 1 every 6 weeks)
Study: 34642366
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hypofractionated stereotactic radiotherapy (HFSRT, [Formula: see text] Gy [Formula: see text] 5 in daily fractions)
Study: 33549029
Drug: Argatroban 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban 0.5 mg/mL
Study: 33549029
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) 1,000 U/mL
Study: 35289096
Drug: Poor communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor communication with good treatment outcome
Study: 35289096
Drug: Poor communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor communication with poor treatment outcome
Study: 35856373
Drug: AS-600 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-600 (600 mg of NAC + 80 mg of propolis)
Study: 35856373
Drug: AS-1,200 (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS-1,200 (1,200 mg of NAC + 160 mg of propolis)
Study: 34663491
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1-g loading dose over 10 minutes, then a 3-g maintenance dose over 24 hours)
Study: 35317983
Drug: Video group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video group (watched educational video twice)
Study: 32193660
Drug: Audio-visual-directed exercise
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-visual-directed exercise training (DVD), thrice-weekly sessions of 15 min for 12 weeks
Study: 34802036
Drug: Hypothermia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia treatment
Study: 35718621
Drug: Intervention H
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention H (High): targeted CPB flow 3.0 L/min/m2 and mean arterial pressure (MAP) 80 mmHg
Study: 35718621
Drug: Intervention N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention N (Normal): targeted CPB flow 2.4 L/min/m2 and MAP 65 mmHg
Study: 35621864
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg subcutaneously within 24 h and 2 weeks after PCI
Study: 35621864
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg/day) alone
Study: 36075591
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human tumor necrosis factor receptor-antibody type II fusion protein, 25 mg subcutaneously, injected once on every Monday and Friday for 3 weeks (6 injections total).
Study: 33206228
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids (KIDIMN)
Study: 32747743
Drug: Intraarticular vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular vancomycin powder (1 g) applied before wound closure
Study: 32847423
Drug: SIBP-01 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIBP-01 (6 mg•kg-1 intravenous dose)
Study: 32847423
Drug: Herceptin® (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin® (6 mg•kg-1 intravenous dose)
Study: 34618684
Drug: AMY-101 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMY-101 (0.1 mg/site) administered via intragingival injections on days 0, 7, and 14
Study: 34618684
Drug: AMY-101 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMY-101 (0.1 mg/site) administered via intragingival injections
Study: 34743231
Drug: Sham-placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-placebo treatment
Study: 34127491
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with intravenous fluid coloading and phenylephrine infusion
Study: 34219653
Drug: CYD-TDV dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD-TDV dengue vaccine
Study: 33482893
Drug: Immediate SDB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate SDB treatment with ASV
Study: 34635547
Drug: GABA 600
Normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA 600 mg
Study: 36375329
Drug: Viloxazine extended-release
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine extended-release (viloxazine ER, Qelbree®), flexible-dose (200-600 mg)
Study: 32886746
Drug: 7-session modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-session modified Mindfulness-Based Cognitive Therapy (MBCT) for 10 weeks with telephone follow-up
Study: 35935625
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg
Study: 33094931
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg TDS for 8 weeks
Study: 33094931
Drug: Calcium tablets
Normalized name: Leucovorin Calcium Tablets
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium tablets as placebo (control)
Study: 37007930
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI)
Study: 35038990
Drug: Support for
Normalized name: GNP Diabetic Support Formula Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support for traditional midwives with a monthly stipend and training from an intercultural broker in intervention communities.
Study: 33211063
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) + Bevacizumab (15 mg/kg IV every 3 weeks) + Oral Cyclophosphamide (50 mg once daily)
Study: 35926990
Drug: PA coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA coaching intervention underpinned by motivational interviewing and cognitive‐behavioural therapy
Study: 34473215
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL IV normal saline 60 minutes before anesthesia)
Study: 34473215
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg IV 60 minutes before anesthesia)
Study: 34790521
Drug: 2-L PEG
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L PEG
Study: 36154349
Drug: Ibuprofen (IBG)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IBG) 400 mg administered 15 min prior to the trial and after 5 h
Study: 36072608
Drug: FF/UMEC/VI 100/62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI 100/62.5/25 mcg
Study: 36072608
Drug: BUD/FOR 400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FOR 400/12 mcg
Study: 34348352
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream (PIM)
Study: 34250712
Drug: Combined IPL/fractional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IPL/fractional Er:YAG treatment
Study: 35775679
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment responders (Group MR)
Study: 32754804
Drug: GAD-alum immunotherapy
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum immunotherapy (recombinant GAD65 conjugated to aluminium hydroxide)
Study: 35879804
Drug: Immediate-release carvedilol-IR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release carvedilol-IR
Study: 34665453
Drug: Myo-inositol (MI)
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol (MI) 4 g/day
Study: 34190055
Drug: Wnt16 gKO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wnt16 gKO mice with high dosage VitD diet
Study: 35055558
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy group (PTG) (n = 19)
Study: 35039498
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (placebo-controlled)
Study: 34626918
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet (ED) - Elental® 160 g/day
Study: 33045216
Drug: Netarsudil 0.02%
Normalized name: NETARSUDIL 0.02% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil 0.02% ophthalmic solution
Study: 32855054
Drug: Morphine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (40 mcg)
Study: 33084081
Drug: Ketamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (20 mg)
Study: 36081295
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g/day)
Study: 32464266
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (DL‐PDT)
Study: 34746999
Drug: Intravenous Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Vitamin C (2 g every 6 hours for 5 days)
Study: 33539744
Drug: Carboplatin-based doublet
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based doublet alone (standard chemotherapy)
Study: 33985942
Drug: Tildrakizumab 200
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 200 mg every 4 weeks (Q4W)
Study: 33985942
Drug: Tildrakizumab 20
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 20 mg Q12W (switched to 200 mg at W24)
Study: 35451678
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg zinc gluconate daily)
Study: 34563627
Drug: High-dose electro-acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose electro-acupuncture (EA) - seven times each chemotherapy cycle for three cycles
Study: 34563627
Drug: Low-dose electro-acupuncture
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose electro-acupuncture (EA) - three times each chemotherapy cycle
Study: 34563627
Drug: High-dose electro-acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose electro-acupuncture (EA)
Study: 32950920
Drug: Large marker
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large marker (14 mm, 2 g)
Study: 35875916
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 μg/kg
Study: 35875916
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 0.5 mg kg ‐1
Study: 33508735
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) with additional parental coaching
Study: 35005205
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise training (60 min/session, twice/week for 24 weeks)
Study: 33038262
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus 12-week intervention (weekly choir rehearsal and daily breathing exercises)
Study: 35475684
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) 60 billion CFU daily for 4 weeks
Study: 33794205
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus chemoradiotherapy (10 mg/kg avelumab intravenously every 2 weeks plus 100 mg/m2 cisplatin every 3 weeks plus intensity‐modulated radiotherapy with standard fractionation of 70 Gy)
Study: 35099133
Drug: Sublingual Nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Nitroglycerin (NTG) administration
Study: 33213378
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day tolvaptan
Study: 33213378
Drug: 7.5 mg/day
Normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/day tolvaptan
Study: 39743172
Drug: Beta-blockers (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (BB)
Study: 35732345
Drug: Febuxostat or
Normalized name: febuxostat Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat or Allopurinol (discontinuation)
Study: 33526287
Drug: Low SMI
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low SMI after neoadjuvant chemotherapy
Study: 34312159
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg calcium propionate (PA)
Study: 32895660
Drug: Selenium 200
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 200 mcg tablets twice daily
Study: 34397746
Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) once daily
Study: 38501300
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis
Study: 34689863
Drug: High-dose urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose urokinase (50,000 IU injected daily, total 100,000 IU per day)
Study: 34689863
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20,000 IU injected daily, total 40,000 IU per day)
Study: 34689863
Drug: High-dose urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose urokinase treatment
Study: 32991046
Drug: D-phenylalanine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-phenylalanine (10 g)
Study: 37301768
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive treatment
Study: 37938495
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESA)
Study: 33069881
Drug: Ornithine phenylacetate
Normalized name: phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine phenylacetate (OP) 10, 15, or 20 g/d
Study: 35679098
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg once weekly
Study: 34214867
Drug: Cerebrolysin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (intravenous as add-on therapy)
Study: 35587322
Drug: Limited adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited adjuvant tamoxifen treatment
Study: 34708706
Drug: Cervical lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cervical lidocaine spray only
Study: 34708706
Drug: Cervical lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cervical lidocaine spray and naproxen tablet
Study: 33377367
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg daily for 4 months)
Study: 32152868
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Therapy for Insomnia (BBT-I)
Study: 35263436
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/day for 120 days
Study: 32367378
Drug: ZnO 30
Normalized name: ZNO 30 MG/ML Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnO 30 mg Zn/kg
Study: 32367378
Drug: ZnO 60
Normalized name: ZNO 60 MG/ML Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnO 60 mg Zn/kg
Study: 32367378
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (30.3 mg Zn/kg diet)
Study: 33795116
Drug: Low-dose everolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose everolimus and low-dose tacrolimus (RADTAC group)
Study: 33795116
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus (TAC group)
Study: 34098331
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine spray
Study: 39007830
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC)
Study: 34913767
Drug: Semi‐hepatic sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi‐hepatic sequential radiotherapy (Group B)
Study: 33944876
Drug: Standard infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard infliximab therapy
Study: 36326260
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of sodium citrate and treprostinil in diluent with magnesium chloride (10 μL/h) with 15 unit-equivalent boluses (150 μL) at 3, 6, and 9 hours after initiation
Study: 36326260
Drug: Arm infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm infusion site
Study: 36326260
Drug: Thigh infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thigh infusion site
Study: 37568242
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam
Study: 36048114
Drug: Low-nicotine dose
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-nicotine dose (3% JUUL)/nonpreferred flavor
Study: 36048114
Drug: High-nicotine dose
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-nicotine dose (5% JUUL)/nonpreferred flavor
Study: 36048114
Drug: High dose/preferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose/preferred flavor
Study: 32207707
Drug: RPMF without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RPMF without local chondroprotective therapy
Study: 35853131
Drug: Motivational interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviews (MI) - 4 sessions at weekly intervals